Circulating biomarkers and their implications in COVID-19 pathogenesis

2024

Full text Open access: Gold Metadata (CSL-JSON)
DOI 10.1051/bioconf/202410001008
Data confidence 70 medium
How this score is calculated

It is built from checkable properties of the record itself: whether the article has a DOI, how many independent sources confirmed its data, whether the required fields are filled in, and how recent the latest confirmation is. Disagreement between sources and a missing identifier lower it. A value of 80 or above means the record was published without further checking; 60 to 79 means it is published at reduced confidence, with a manual check advisable. A record verified by an editor by hand is never pushed below 90 by a recalculation. This scores our data about the article, not the article itself.

Abstract

COVID-19 is an infectious disease caused by a new SARS-CoV-2 coronavirus. The coronavirus infection emerged in China in 2019 and quickly disseminated globally in a short time. According to WHO about 100 million people were infected in 2021, rising to 500 million in 2022. In most cases, the trajectory of COVID-19 concludes with a positive result. However, the likelihood of experiencing a serious form of the disease is quite high. A severe form of coronavirus infection causes a storm of reactions in the body. The increased release of cytokines into the blood in response to viral infection is called cytokine release syndrome and causes acute respiratory distress syndrome and multi-organ failure. Timely control of cytokine storm with drugs such as immunomodulators and cytokine antagonists, as well as reduction of lung inflammatory cell infiltration is the main way to improve treatment effectiveness and decrease the mortality rate in individuals suffering from COVID-19.